fSome patients opted to nominate two HCPs in instances where HCPs worked closely together and sometimes made joint visits to patients. gGuidelines from the Royal College of Physicians [24] suggest that professionals should avoid initiating discussions immediately after a move to a care home; discussions are advised to be postponed until once individuals are more settled. hThe data were collected immediately prior to the Mental Capacity Act 2005 becoming law

in 2007. iAll participants were anonymised. Patients were given a number which was also linked to the different study sites. For example currently patient 104 is the fourth patient interviewed from Site 1. We have used a generic term HCP for health care Inhibitors,research,lifescience,medical professionals interviewed

Inhibitors,research,lifescience,medical to avoid identification, just indicating the different sites and distinguishing between inhibitor Ruxolitinib discussion group interview data (DGP) and follow up interview data (FU). Participants included one GP, several district nurses, community matrons and Macmillan Inhibitors,research,lifescience,medical nurses. jIn part this may have been because we did not prompt fuller discussions of their preferences. In some instances we also looked for cues of patients, particularly when we had been briefed by health care professionals to take an indirect approach. Some patients quickly changed the subject, several became emotional. Competing interest The Authors declare that there is no competing interest. Authors’ contributions KC and JS conceived the project and secured project funding. KC, JS, KA and Inhibitors,research,lifescience,medical NM contributed to the design of the study, development of the data collection tools. KA and NM undertook the data collection. All authors contributed to data analysis and helped draft the manuscript. All authors have read and approved the final manuscript. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1472-684X/11/15/prepub

Inhibitors,research,lifescience,medical Acknowledgements We thank all participants for their time and contributions from colleague Davina Porock. Funding The study was Dacomitinib funded by the Mid Trent Cancer Network, PCTs in Lincolnshire and the National End of Life Programme. The funders approved the study design but had no role in determining the design and no input into: the collection, analysis, and interpretation of data; the writing of the report; and in the decision to submit the article for publication. The views and opinions expressed herein are those of the authors. All authors declare independence from the study funders.
Tens of thousands of people in North America experience homelessness every year [1,2]—that is, live in conditions unfit for human habitation or temporary or emergency accommodations without housing alternatives [3]—and many thousands more are at risk of homelessness at any given time [1,2].